319. Outcome of Initial Antibiotic Treatments among Hospitalized Patients with Hospital- and Healthcare-Associated Bacterial Infections in Brazil: Findings of the RECOMMEND Study
Session: Poster Abstract Session: HAI: Multi Drug Resistant Gram Negatives
Thursday, October 27, 2016
Room: Poster Hall
Posters
  • Brazil RECOMMEND IDWeek 2016 poster_FOR UPLOAD.pdf (333.3 kB)
  • Background: In recent years, increased rates of multidrug-resistant (MDR) Gram-negative bacterial infections have been observed globally. Recent real-world data documenting first-line treatments and associated clinical outcomes are lacking. This study assessed outcomes associated with initial antibiotic treatments in hospitalized patients with nosocomial pneumonia (NP), complicated urinary tract infections (cUTI) and intra-abdominal infections (cIAI) in Brazil.  

    Methods: This was a retrospective observational study (NCT02364284) involving medical chart review of adults hospitalized with one of the three infections across 4 sites in Brazil. The study period was from July 1, 2013 to June 30, 2014. Patients were followed from index date until death while hospitalized, up to 30-days post discharge, or the end of follow-up period (December 2014) if not yet discharged. Initial antibiotic treatment (IAT), defined as the antibiotics received during the 48 hours post-therapy initiation, and associated outcome (success, failure, and indeterminate) were assessed. MDR was defined as exhibiting resistance to one drug in at least three antibiotic classes. Study data were documented using descriptive measures. 

    Results: The study included 82 patients with cUTI (mean age: 58 years; females: 59%), 89 patients with cIAI (mean age: 58 years; females: 52%), and 100 patients with NP (mean age: 65 years; females: 25%). Proportion of patients with an MDR infection was 36% for patients with cUTI, 22% for cIAI and 27% for NP. IAT as monotherapy was observed in 79% of cUTI patients, 54% of cIAI patients, and 68% of NP patients. The two most commonly observed IATs for the three infection types are presented in Figure 1. Reasons for stopping the IAT are presented in Figure 2. The overall IAT failure rate for cUTI, cIAI and NP were 74%, 79% and 90% respectively. In-hospital all-cause mortality rates for were cUTI, cIAI and NP were 46%, 56% and 72% respectively.

    Conclusion: High rates of IAT failure and all-cause mortality highlight an unmet need among hospitalized patients with common hospital-acquired or healthcare-associated Gram-negative infections. Limitations associated with an observational study should be considered when interpreting these results.  

    * Multiple reasons per patient might be reported; cUTI: 9 patients had 2 reasons, 1 patient had 3 reasons, cIAI: 9 patients had 2 reasons, NP: 10 patients had 2 reasons.

     

    Sudeep Karve, PhD, Medical Evidence & Observational Research Center, AstraZeneca, Gaithersburg, MD, Kellie Ryan, MPH, AstraZeneca, Gaithersburg, MD, Esther Pascual, PhD, Medical Evidence and Observational Research Center, AstraZeneca, Madrid, Spain, Pascale Peeters, MD, Real-World & Late Phase Research, Quintiles, Saint-Ouen Cedex, France, Sonia Rojas-Farreras, MSc, Real-World & Late Phase Research, Quintiles, Barcelona, Spain, Elisa Baelen, MSc, Real-World & Late Phase Research, Quintiles, St. Prex, Switzerland and Jesus Rodriguez-Bano, MD, Infectious Diseases and Clinical Microbiology, Hospital Universitario Virgen Macarena, Seville, Spain

    Disclosures:

    S. Karve, AstraZeneca: Employee and Shareholder , Company stock and Salary

    K. Ryan, AstraZeneca: Employee and Shareholder , Company stock and Salary

    E. Pascual, AstraZeneca: Employee and Shareholder , Company stock and Salary

    P. Peeters, Quintiles: Employee , Salary

    S. Rojas-Farreras, Quintiles: Employee , Salary

    E. Baelen, Quintiles: Employee , Salary

    J. Rodriguez-Bano, AstraZeneca: Grant Investigator and Scientific Advisor , Grant recipient
    MSD: Scientific Advisor and Speaker's Bureau , Speaker honorarium
    Roche: Scientific Advisor , Consulting fee
    Achaogen: Scientific Advisor , Consulting fee
    Basilea: Scientific Advisor , Consulting fee
    Astellas: Speaker's Bureau , Speaker honorarium
    Pfizer: Speaker's Bureau , Speaker honorarium
    Novartis: Speaker's Bureau , Speaker honorarium
    Gilead: Grant Investigator , Grant recipient
    Aicuris: Grant Investigator , Grant recipient

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.